Thrombin-induced Hyperactivity of Platelets of Young Stroke Patients

2002 ◽  
Vol 88 (12) ◽  
pp. 931-937 ◽  
Author(s):  
Kristof Vanschoonbeek ◽  
Marion Feijge ◽  
Jeffrey Keuren ◽  
H. Hemker ◽  
Jan Lodder ◽  
...  
Keyword(s):  
Peripheral Arterial Disease ◽  
Platelet Activation ◽  
Young Patients ◽  
Vascular Diseases ◽  
Arterial Disease ◽  
Platelet Response ◽  
Stroke Patients ◽  
Protease Activated Receptor 1 ◽  
The Subject ◽  
Peripheral Arterial

SummaryActivated platelets are implicated in the development of premature arterial vascular diseases, in particular ischemic stroke. Since elevated cytosolic [Ca2+]i is an integrative marker of platelet activation, we determined the generation of Ca2+ signal in stimulated platelets from 26 young patients recuperating from stroke, 20 patients with symptomatic peripheral arterial disease, and 56 healthy volunteers. Even in the presence of aspirin, the platelets from various individuals showed highly different thrombin-induced Ca2+ responses. On average, the thrombin-induced Ca2+ response was increased for platelets from either patient group in comparison to the controls (P <0.04). Relatively more stroke patients had high-responsive platelets (27%, 7/26) than patients with peripheral arterial disease (10%, 2/20) or healthy subjects (4%, 2/56). The average prothrombinase activities of platelets from patients and controls were similar, but 3 out of 6 patients with increased thrombin-induced Ca2+ responses also exhibited high prothrombinase activity. In a follow-up study, the subject-dependent thrombin-induced Ca2+ response was found to correlate strongly with the platelet response to protease-activated receptor 1 (PAR1) agonist (r = 0.91), but was not linked to the PlA1/2 polymorphism. It is concluded that a significant part of young patients with stroke have platelets with hyperactivity toward thrombin, which is not normalised by aspirin treatment. Furthermore, the subject-dependent variation in thrombin-induced signalling is likely to involve PAR1-mediated platelet activation.

Platelet activation during treadmill exercise in patients with chronic peripheral arterial disease

1981 ◽  
Vol 23 (3) ◽  
pp. 215-223 ◽  
Author(s):  
G Baele ◽  
H Bogaerts ◽  
D.L Clement ◽  
R Pannier ◽  
F Barbier
Keyword(s):  
Peripheral Arterial Disease ◽  
Platelet Activation ◽  
Treadmill Exercise ◽  
Arterial Disease ◽  
Peripheral Arterial

scholarly journals Nanomaterial-Mediated Theranostics for Vascular Diseases

2020 ◽  
Vol 2 (1) ◽  
pp. 1-15
Author(s):  
Swati Agrawal ◽  
Sunil K. Nooti ◽  
Harbinder Singh ◽  
Vikrant Rai
Keyword(s):  
Peripheral Arterial Disease ◽  
Therapeutic Agent ◽  
Molecular Level ◽  
Vascular Diseases ◽  
Arterial Disease ◽  
Imaging Studies ◽  
Leg Muscles ◽  
Diagnostic Agents ◽  
Peripheral Arterial ◽  
Complementary Strategy

Nanotechnology could offer a new complementary strategy for the treatment of vascular diseases including coronary, carotid, or peripheral arterial disease due to narrowing or blockage of the artery caused by atherosclerosis. These arterial diseases manifest correspondingly as angina and myocardial infarction, stroke, and intermittent claudication of leg muscles during exercise. The pathogenesis of atherosclerosis involves biological events at the cellular and molecular level, thus targeting these using nanomaterials precisely and effectively could result in a better outcome. Nanotechnology can mitigate the pathological events by enhancing the therapeutic efficacy of the therapeutic agent by delivering it at the point of a lesion in a controlled and efficacious manner. Further, combining therapeutics with imaging will enhance the theranostic ability in atherosclerosis. Additionally, nanoparticles can provide a range of delivery systems for genes, proteins, cells, and drugs, which individually or in combination can address various problems within the arteries. Imaging studies combined with nanoparticles helps in evaluating the disease progression as well as the response to the treatment because imaging and diagnostic agents can be delivered precisely to the targeted destinations via nanocarriers. This review focuses on the use of nanotechnology in theranostics of coronary artery and peripheral arterial disease.

Abstract T P338: To Evaluate the Efficacy and Safety of Cilostazol in Ischemic Stroke Patients with Peripheral Arterial Disease (SPAD) Study: Methodology and Baseline Data

Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Jiann-Shing Jeng ◽  
Li-Ming Lien ◽  
Sien-Tsong Chen ◽  
Chung Y. Hsu ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Ischemic Stroke ◽  
Peripheral Arterial Disease ◽  
Carotid Stenosis ◽  
Smoking Habit ◽  
Arterial Disease ◽  
Stroke Patients ◽  
Vascular Events ◽  
Safety And Efficacy ◽  
Peripheral Arterial

Background and Purpose: Ischemic stroke often co-exists with peripheral arterial disease (PAD). Patients with polyvascular diseases carry higher risks of vascular events and death. We initiated a study to evaluate the safety and efficacy of cilostazol in ischemic Stroke patients with PAD (SPAD) and have been taking aspirin for stroke prevention. Methods: The SPAD study is a prospective, multicenter, national, double-blinded, placebo-controlled, randomized trial. Patients with previous ischemic stroke or TIA who have been taking aspirin (100 mg per day), aged 50 years or older, with PAD in the lower limbs based on ankle-brachial index (ABI) <1.0 were randomized to the treatment group with cilostazol (200 mg/day) or the placebo group with a 1:1 basis. Each patient is periodically followed-up for one year. The primary endpoint of the study is the change in the ABI. The secondary endpoints are the change in the common carotid artery intima-media thickness (IMT); major cardiovascular events, including recurrent stroke, myocardial infarction, unstable angina, other vascular events, and all death; and the safety, including major bleeding events, hemorrhagic stroke, and any death. Results: From September, 2010 to July, 2012, a total of 800 patients (male, 59.9%; female, 40.1%; average age, 70.4±9.3 years) were enrolled in the SPAD study, including 722 (90.2%) with ischemic stroke or 78 (9.8%) with TIA. Several atherosclerotic risk factors were commonly seen in this study population, including hypertension (88%), diabetes mellitus (48%), hypercholesterolemia (54%), smoking habit (41%), and carotid stenosis (15%). The distribution of baseline ABI were 0.90-0.99 (n=294), 0.70-0.89 (n=371), and <0.70 (n=136). Patients with lower ABI were more frequently associated with old age, lower body mass index, smoking habit, diabetes mellitus, carotid stenosis ≥50%, and higher systolic blood pressure. Conclusions: The SPAD trial is the first study to evaluate the safety and efficacy of dual antiplatelets, aspirin plus cilostazol, in ischemic stroke patients with PAD. The trial findings are expected to help in choosing better strategy for prevention of vascular events in this polyvascular disease.

Identification and Management of Polyvascular Disease in Patients with Noncardioembolic Ischaemic Stroke

2008 ◽  
Vol 3 (4) ◽  
pp. 237-248 ◽  
Author(s):  
Antonio Carolei ◽  
Angel Chamorro ◽  
Patrice Laloux ◽  
Didier Leys ◽  
Joachim Röther ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Peripheral Arterial Disease ◽  
Ischaemic Stroke ◽  
Ankle Brachial Index ◽  
Arterial Disease ◽  
Routine Practice ◽  
Stroke Patients ◽  
Routine Examination ◽  
Personal View ◽  
Peripheral Arterial

Recent registry results have shown that polyvascular disease (PolyVD), usually manifested as coronary heart disease or peripheral arterial disease (PAD), is a marker of increased morbidity and mortality in patients with noncardioembolic ischaemic stroke, but is often inadequately assessed. This Personal View Paper advocates routine examination for PolyVD in such patients. Peripheral arterial disease can be readily detected in routine practice by measurement of the ankle-brachial index. This paper makes recommendations for risk stratification, discharge documentation and, where possible, management of ischaemic stroke patients with PolyVD.

Sign in / Sign up

Export Citation Format

Share Document